Insurers forcing surgeons to use specific bone grafting products - Mark Copeland on BoneChan #38

11 Aug 2024 · 1 min
0:52

Mark Copeland explains how insurers and hospitals force surgeons to use specific bone graft products based on reimbursement, not clinical outcomes. Cell-based demineralized bone matrix products are being abandoned because insurers won't pay for them in certain cases, pushing surgeons back to traditional options. Hospital administrators effectively become salespeople, steering doctors through financial pressure rather than evidence.

Chapters

More from Tiger

1:00:35
youtube.com

BoneChat #146 - Raising Capital, Protecting Equity, Dilution & Staying Lean

1w ago
58:35
youtube.com

BoneChat #145 - ASC Robots, Direct-to-Patient Marketing & Ortho Startup Reality

2w ago
57:20
youtube.com

BoneChat #144 - Defining the Standard of Care for Orthopedic Tissue Preservation & Restoration

4w ago
56:40
youtube.com

BoneChat #143 - AI-Driven MedTech Sales, Startup Traps, & Orthopedic Commercialization

1mo ago
1:20
youtube.com

Reverse Shoulder movement in the US

1mo ago
1:03:29
youtube.com

BoneChat #142 - Fastest-Growing Ortho Segments, Reverse Shoulder & Joint Preservation Rollups

1mo ago
59:10
youtube.com

BoneChat #141 - Disrupting Surgical Visualization: Single-Use 4K Scopes with Richard McKillop

1mo ago
57:56
youtube.com

BoneChat #140 - Transforming Knee Rehab, Patient Experience, and MedTech Go-to-Market

1mo ago
0:36
youtube.com

How to find early adopters in Ortho.

2mo ago
0:35
youtube.com

The Importance of Controlling Your Own Destiny in Deals

2mo ago
0:50
youtube.com

Red Flags in Business Partnerships

2mo ago
See all content